Status:

COMPLETED

Dasatinib in Relapsed Chronic Lymphocytic Leukemia

Lead Sponsor:

Massachusetts General Hospital

Collaborating Sponsors:

Brigham and Women's Hospital

Dana-Farber Cancer Institute

Conditions:

Chronic Lymphocytic Leukemia

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this research study is to see if Dasatinib is effective and safe to give to people with relapsed chronic lymphocytic leukemia (CLL) and to determine the effects of the drug on LYN kinas...

Detailed Description

* After the screening procedures confirm that the participant is eligible and willing to participate in the research study, they will have the following tests and procedures. * Dasatinib is given oral...

Eligibility Criteria

Inclusion

  • 18 years of age or older
  • CLL/SLL with cells positive by flow cytometry (or immunostaining) for CD19, CD23 and CD. Patients may be CD23 negative as long as they are also cyclin D1 negative.
  • Must have failed at least 1 prior fludarabine containing regimen or have failed at least 2 non-fludarabine containing regimens or have a contraindication to fludarabine use
  • ECOG performance status of 2 or better
  • Adequate organ function to tolerate chemotherapy
  • Adequate method of contraception

Exclusion

  • Pregnant or breast-feeding women
  • Uncontrolled angina within 3 months
  • Diagnosed or suspected congenital long QT syndrome
  • History of clinically significant ventricular arrhythmias
  • Prolonged QTc interval on pre-entry electrocardiogram
  • Uncontrolled hypertension
  • Drugs that are generally accepted to have a risk of causing Torsades de Pointes
  • Patient known to be HIV positive
  • Known significant bleeding disorder unrelated to CLL
  • Drugs that interfere with platelet function or coagulation must be stopped at least 7 days prior to entry

Key Trial Info

Start Date :

December 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2013

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT00438854

Start Date

December 1 2006

End Date

March 1 2013

Last Update

December 13 2017

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

2

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115